LRRC4C

Across TCGA pan-cancer cohorts, LRRC4C Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LRRC4C data layer compared with 22 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher LRRC4C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC4C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, HNSC, and UCEC are the cancer types where LRRC4C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.124	0.706	<.001	24	view →
HNSC	OS	Median	IV	0.511	0.719	.013	21	view →
UCEC	DFS	Median	All	0.942	0.622	.013	20	view →
OV	DFS	Median	II,III,IV	0.290	0.542	.040	18	view →
ESCA	OS	Median	III,IV	0.108	0.574	<.001	12	view →
SKCM	DFS	Median	III,IV	0.287	0.678	.001	11	view →
READ	OS	Median	III,IV	0.328	0.751	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LRRC4C–ACC (OS)

Open the ACC breakdown →